Preparation of patient doses of 177Lu-DOTA-TATE using indigenously produced 177Lu: The Indian experience

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 3, 2011, Pages 395-400

  Das, Tapas ^a   Chakraborty, Sudipta ^a   Kallur, Kumar G ^b   Venkatesh, Meera ^a   Banerjee, Sharmila ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b Bangalore Institute of Oncology   (India)

Author keywords

177Lu; DOTA TATE; neuroendocrine tumors; patient dose

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTATE LU 177; LUTETIUM 177; UNCLASSIFIED DRUG;

ARTICLE; DRUG PURITY; DRUG QUALITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; ISOTOPE LABELING; LUNG METASTASIS; NEUROENDOCRINE TUMOR; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; QUALITY CONTROL;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DESIGN; HUMANS; INDIA; LUTETIUM; NUCLEAR MEDICINE; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; QUALITY CONTROL; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SOMATOSTATIN;

EID: 79960043555     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2010.0881     Document Type: Article

References (13)

1. de Visser M, Verwijnen SM, de Jong M. Improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biother Radiopharm 2008;23:137.
2. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754.
3. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,- Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124.
4. van Essen M, Krenning EP, de Jong M, et al. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007;46:723.
5. Esser JP, Krenning EP, Teunissen JJM, et al. Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: Which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006;33:1346.
6. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with novel radiolabelled somatostatin analogue [177Lu- DOTA0,Tyr3]octreotate. Eur J Nucl Med 2003;30:417.
7. Kwekkeboom DJ, Mueller-brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46:62.
8. Breeman WAP, de Jong M, Visser TJ, et al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30:917.
9. Volkert WA, Hoffman TJ. Therapeutic radiophamaceuticals. Chem Rev 1999;99:2269.
10. Das T, Chakraborty S, Banerjee S, et al. On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor. Appl Radiat Isot 2007;65:301.
11. Pillai MRA, Chakraborty S, Das T, et al. Production logistics of 177Lu for radionuclide therapy. Appl Radiat Isot 2003;59:109.
12. Dvorakova Z, Henkelman R, Lin X, et al. Production of 177Lu at new research reactor FRM-II: Irradiation yield of 176Lu(n,g)177Lu. Appl Radiat Isot 2008;66:147.
13. Knapp FF, Ambrose KR, Beets AL, et al. Nuclear Medicine Program Progress Report for Quarter Ending September 30, Oak Ridge, TN: Oak Ridge National Laboratory, 1995;6.